For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
7
views
11
references
 Top references
cited by
73
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      2,107
      similar
       All similar
      • Record: found
      • Abstract: not found
      • Article: not found

      Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure) showed that dapagliflozin added to other guideline-recommended therapies reduced the risk of mortality and heart failure hospitalization and improved symptoms in patients with heart failure and reduced ejection fraction. We examined the effects of dapagliflozin according to age, given potential concerns about the efficacy and safety of therapies in the elderly.

          Related collections

          Most cited references11

          • Record: found
          • Abstract: not found
          • Article: not found

          An update on the clinical consequences of polypharmacy in older adults: a narrative review

          Jonas W. Wastesson, Lucas Morin, Edwin Tan … (2018)
          Article 0 comments Cited 154 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Semiparametric regression for the mean and rate functions of recurrent events

            L Wei, I. Yang, Z Ying … (2000)
            Article 0 comments Cited 142 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure.

              John J V McMurray, Henry Krum, William T. Abraham … (2016)
              Among patients with chronic heart failure, angiotensin-converting-enzyme (ACE) inhibitors reduce mortality and hospitalization, but the role of a renin inhibitor in such patients is unknown. We compared the ACE inhibitor enalapril with the renin inhibitor aliskiren (to test superiority or at least noninferiority) and with the combination of the two treatments (to test superiority) in patients with heart failure and a reduced ejection fraction.
              Article 0 comments Cited 87 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Title: Circulation
                Abbreviated Title: Circulation
                Publisher: Ovid Technologies (Wolters Kluwer Health)
                ISSN (Print): 0009-7322
                ISSN (Electronic): 1524-4539
                Publication date Created: November 17 2019
                Publication date (Electronic): November 17 2019
                Affiliations
                [1 ]Universidad Nacional de Córdoba, Argentina
                [2 ]BHF Cardiovascular Research Centre, University of Glasgow, UK; Cardiovascular Institute, Azienda Ospedaliero-Universitaria di Ferrara, Cona, Italy
                [3 ]Instituto do Coracao (InCor), Hospital das Clínicas Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil
                [4 ]BHF Cardiovascular Research Centre, University of Glasgow, UK
                [5 ]General Clinical Research Center and Division of Cardiology, Taipei Veterans General Hospital and National Yang-Ming University, Taiwan
                [6 ]Department of Myocardial Disease and Heart Failure, National Medical Research Center of Cardiology of Russia, Moscow
                [7 ]Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA
                [8 ]Section of Endocrinology, Yale School of Medicine, New Haven, CT
                [9 ]Department of Cardiology, Rigshospitalet Copenhagen University Hospital, Denmark
                [10 ]Saint Luke's Mid America Heart Institute, University of Missouri- Kansas City; The George Institute for Global Health, University of New South Wales, Sydney, Australia
                [11 ]Center for Heart Diseases, University Hospital, Wroclaw Medical University, Poland
                [12 ]TIMI Study Group, Brigham and Women's Hospital, Boston, MA
                [13 ]Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison
                [14 ]Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Warsaw, Poland
                [15 ]Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
                Article
                DOI: 10.1161/CIRCULATIONAHA.119.044133
                PubMed ID: 31736328
                SO-VID: 4eede844-3a9d-4e34-9e0c-ebc5e3057d3f
                Copyright © © 2019
                History

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content2,107

                See all similar

                Cited by78

                See all cited by

                Most referenced authors645

                See all reference authors